SCHEMBL20774262

SCHEMBL20774262

O=C1c2ccccc2C(=O)N1CC1(C(=O)O)CCCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
ALDH1A1 P00352 4/20 0.46
LMNA P02545 1/20 0.46
BRD4 O60885 1/20 0.45
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ACHE P22303 1/20 0.41
HRH1 P35367 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7847932 0.98 CA12 (0.49) CA12CA9ALDH1A1LMNABRD4
SCHEMBL21496644 0.93 CA12 (0.53) CA12CA9ALDH1A1KMT2AGAA
SCHEMBL22190358 0.78 CA12 (0.51) CA12CA9ALDH1A1LMNAKMT2A
SCHEMBL22556267 0.77 CA12 (0.50) CA12CA9ALDH1A1LMNAKMT2A
SCHEMBL462922 0.75 CYP2C19 (0.46) ALDH1A1LMNABRD4KMT2AHPGD
SCHEMBL25959262 0.75 CA12 (0.46) CA12CA9ALDH1A1LMNAKMT2A
SCHEMBL516828 0.74 TDP1 (0.51) ALDH1A1HPGDSMN1; SMN2ACHEKDM4E
SCHEMBL8284161 0.73 LMNA (0.51) CA12CA9ALDH1A1LMNAKMT2A
SCHEMBL15968001 0.73 CA12 (0.49) CA12CA9ALDH1A1KMT2AGAA
SCHEMBL9630924 0.73 MAPT (0.44) CA12CA9ALDH1A1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family CTXT PTY LIMITED (AU) 2021-12-09 US disclosed
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family CTXT PTY LIMITED (AU) 2021-12-09 US disclosed
EP-3676266-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY Ctxt Pty Ltd (AU) 2020-07-08 EP disclosed
WO-2019043139-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY CTXT PTY LIMITED (AU) 2019-03-07 WO disclosed
WO-2019043139-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY CTXT PTY LIMITED (AU) 2019-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family KAT5, KAT6A, KAT2A CA12 4594/4885CA9 4651/4885ALDH1A1 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.